Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III disappointment for GSK/Tolerx-partnered drug follows last fall's Phase III miss by Lilly and MacroGenics' anti-CD3 antibody in same indication.